COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

The Lung Injury, Repair, and Remodeling (LIRR) Study Section reviews applications that focus on lung development and the response of non-vascular pulmonary tissue or cells to injury, repair, fibrosis, and barrier function. Among the mechanistic processes considered are signal transduction, control of gene expression, cell proliferation, cell differentiation, cell death, and cell-cell and cell-matrix interactions. Integrative processes include inflammation, tissue repair, leukocyte trafficking, regulation of extracellular matrix, and effects of alveolar macrophages and blood components such as coagulation factors and complement.

The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.


  • Lung injury including but not limited to:
    • lung injury caused by reactive oxygen and nitrogen species, hypoxia, acute infection and sepsis, mechanical ventilation, alcohol, nicotine, and environmental and other toxic agents.
    • studies addressing lung epithelium injury, leukocyte contributions to lung injury, normal and abnormal lung permeability, and mechanisms of resolution, repair, and remodeling.
  • Pulmonary fibrosis and interstitial lung diseases:
    • granulomatous diseases (such as sarcoidosis), idiopathic pulmonary fibrosis, interstitial pneumonias, and lymphangioleiomyomatosis.
    • involvement of mesenchymal stem cells, epithelium dysfunction, and alveolar macrophages.
  • Lung fluid balance, including:
    • epithelial (ion channels, aquaporins, etc.).
    • interstitium and lymphatic function.
    • pulmonary edema, when not primarily restricted to the pulmonary vasculature.
  • Pleural diseases, including:
    • infections, dysplasias, hyperplasias, and other non-malignant proliferative disorders and inflammatory processes.
  • Lung development and maturation:
    • includes mechanisms of normal and abnormal lung development.
    • differentiation of alveolar epithelial cells.
    • interactions between mesenchymal cells, epithelial cells and immune cells.
    • neonatal and pediatric lung syndromes and diseases (e.g., bronchopulmonary dysplasia).
  • Lung stem cell biology in the context of:
    • lung development and repair.
    • validation of bioengineering strategies for lung regeneration.
  • Pulmonary surfactant biology including:
    • expression and post-translational processing and trafficking of surfactant proteins in lung epithelium.
    • surfactant lipids.
    • lung diseases associated with surfactant dysfunction and/or deficiency.
    • surfactant replacement therapy.
  • Lung innate and adaptive immunity in the context of:
    • lung development.
    • lung injury, repair and remodeling.
  • Lung diseases and syndromes include but are not limited to:
    • Acute Lung Injury (ALI).
    • Acute Respiratory Distress Syndrome (ARDS).
    • Bronchopulmonary Dysplasia (BPD).
    • Chronic Obstructive Pulmonary Disease (COPD), primary focus on emphysema.
    • Lymphangioleiomyomatosis (LAM).
    • Pulmonary fibrosis.

Shared Interests and Overlaps

There are shared interests between LIRR and Lung Cellular, Molecular and Immunobiology (LCMI). Applications focused on innate and adaptive immunity in the context of lung injury and disorders that include ALI, ARDS, BPD, COPD, LAM and pulmonary fibrosis, may be reviewed in LIRR. Applications focused on diseases of upper airways such as asthma, chronic bronchitis, and cystic fibrosis may be reviewed in LCMI. COPD applications focused on emphysema (alveolar region) are reviewed in LIRR while those focused on chronic bronchitis (upper airways) may be reviewed in LCMI.

There are shared interests between LIRR and Respiratory Integrative Biology and Translational Research (RIBT). Applications focused on lung injury and repair which involve epithelial cells, macrophages or other cell types may be reviewed in LIRR. Applications focused on lung vascular cells may be reviewed in RIBT. RIBT also reviews applications focused on angiogenesis in the context of lung development and bronchopulmonary dysplasia (BPD).

There are shared interests between LIRR and Systemic Injury by Environmental Exposure (SIEE). Applications addressing adverse effects of environmental or other toxicants on the lung in the context of lung development, lung injury/repair, emphysema, and interstitial lung diseases such as sarcoidosis and asbestosis may be reviewed in LIRR study section. Other aspects of lung toxicology may be reviewed in SIEE.

There are shared interests between LIRR and Surgery, Anesthesiology, and Trauma Study Section (SAT). Applications associated with acute lung injury (ALI) caused by sepsis, those focused on the mechanisms underlying the pathogenesis of ALI and development of stem cell-based and pharmacological approaches for treatment may be reviewed in LIRR study section. Applications involving study of systemic injury and responses to sepsis may be appropriate for SAT.

There are shared interests between LIRR and bioengineering-related study sections, Bioengineering, Technology, and Surgical Sciences (BTSS) and Biomaterials and Biointerfaces Study Section (BMBI). Applications focused on lung tissue engineering that involve validation of bioengineering strategies for lung regeneration may be reviewed in LIRR study section. Applications involving early stages of development of these strategies and technologies may be more appropriate for BTSS or BMBI.

There are shared interests between LIRR and Cellular Mechanisms in Aging and Development (CMAD). Applications focused on cell senescence, proteostasis, and tissue repair & regeneration in the context of aging are typically reviewed CMAD. Applications which focus on molecular and cellular mechanisms of chronic lung diseases linked to aging, such as COPD and pulmonary fibrosis, may be reviewed in LIRR.

There are shared interests between LIRR and Development-1 (DEV 1). Developmental biology applications focused on embryonic and postnatal lung development are appropriate for review in LIRR. Applications addressing early embryonic development may be reviewed in DEV1.

There are shared interests between LIRR and Pregnancy and Neonatology (PN). Fetal biology and neonatology applications are typically reviewed in PN. However, applications which focus on fetal and postnatal lung development and lung diseases associated with a defect in lung development, such as BPD, may be reviewed in LIRR. ​